Pluristem Gains Approval For Muscle Regeneration Trial

Pluristem Therapeutics, a developer of placenta-based cell therapies, announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body in Germany, to commence a Phase I/II study to assess the safety and efficacy of its treatment for the regeneration of injured gluteal musculature following total hip replacement. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. The company is headquartered in Haifa, Israel with offices the US.